Indeed, some data suggest that EZH2 inhibition may be detrimental to cancer care by causing a robust switch in cell fate through activation of pluripotency networks, which ultimately promote tumor relapse (de Vries et al, 2015; Wassef & Margueron, 2017). The gene discussed is EZH2; the disease is cancer.